Comment on: "Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus"

Clin Pharmacokinet. 2015 Apr;54(4):447-8. doi: 10.1007/s40262-015-0248-4.

Authors

Emanuel Raschi¹, Elisabetta Poluzzi, Fabrizio De Ponti

Affiliation

¹ Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, Via Irnerio, 48, 40126, Bologna, Italy.

PMID: 25721222
DOI: 10.1007/s40262-015-0248-4

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Diabetes Mellitus, Type 2 / metabolism*
Dipeptidyl-Peptidase IV Inhibitors / pharmacokinetics*
Humans
Liver Diseases / metabolism*
Receptors, Glucagon / agonists*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Receptors, Glucagon